High Dose Nimodipine Treatment Adjunct - 1
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000332
Collaborator
Washington D.C. Veterans Affairs Medical Center (U.S. Fed)
0
1
23
0
Study Details
Study Description
Brief Summary
The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
High Dose Nimodipine Pharmacotherapy Adjunct
Actual Study Start Date
:
May 1, 1998
Actual Primary Completion Date
:
Jan 1, 2000
Actual Study Completion Date
:
Apr 1, 2000
Outcome Measures
Primary Outcome Measures
- Stimulated and non-stimulated craving []
- Stimulated and non-stimulated withdrawal []
- Anxiety, depression []
- Heart rate []
Eligibility Criteria
Criteria
Ages Eligible for Study:
22 Years
to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Washington DC VA | Washington | District of Columbia | United States | 20422 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- Washington D.C. Veterans Affairs Medical Center
Investigators
- Principal Investigator: Steven Deutsch, M.D., Washington D.C. Veterans Affairs Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000332
Other Study ID Numbers:
- NIDA-3-0009-1
- Y01-3-0009-1
First Posted:
Sep 21, 1999
Last Update Posted:
Feb 24, 2017
Last Verified:
Dec 1, 2002
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: